Status:
RECRUITING
A Study to Learn About Somatrogon in Patients With Pediatric Growth Hormone Deficiency (p GHD) in India.
Lead Sponsor:
Pfizer
Conditions:
Dwarfism, Pituitary
Eligibility:
All Genders
3-17 years
Brief Summary
The purpose of this study is to learn about the safety of Somatrogon for the treatment of pediatric growth hormone deficiency (p GHD) in India. Pediatric GHD is a condition caused by too less amounts...
Eligibility Criteria
Inclusion
- Prescription of Somatrogon for p GHD in participants aged 3 years or more.
- Evidence of a personally signed and dated informed consent document indicating that the participant (or a legally acceptable representative) has been informed and agree to all pertinent aspects of the study. Assent will also be sought from children of applicable age in line with national guidance. In all cases, the treating physician responsible for enrolling the participant into the study will assess the appropriateness of gaining assent from a participant (or a legally acceptable representative) at their discretion during routine clinical care.
Exclusion
- Participation in any interventional clinical trials at the time of enrollment.
Key Trial Info
Start Date :
January 30 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 5 2028
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06587035
Start Date
January 30 2025
End Date
September 5 2028
Last Update
January 7 2026
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Shivajoyti Clinic
Bengaluru, Karnataka, India, 560008
2
Apollo Children's Hospital
Chennai, Tamil Nadu, India, 600006
3
G Kuppuswamy Naidu Memorial Hospital
Coimbatore, Tamil Nadu, India, 641037
4
Apollo Speciality Hospital
Madurai, Tamil Nadu, India, 625020